Search

Displaying results 1311 - 1320 of 3888 in total
  1. Drug

    Influenza A Virus A/Victoria/4897/2022 IVR-238 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17994
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

    Mixtures: Fluzone High Dose Northern Hemisphere, Fluzone High Dose Northern Hemisphere
  2. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.

  3. Target

    DNA gyrase subunit A

    go.drugbank.com/bio_entities/BE0008382
    TargetEscherichia coli (strain K12)

    This makes better substrates for topoisomerase IV (ParC and ParE) which is the main enzyme that unlinks newly replicated chromosomes in E.coli (PubMed:9334322). … bacterial gyrases; at comparable concentrations E.coli gyrase introduces more supercoils faster than M.tuberculosis gyrase, while M.tuberculosis gyrase has higher decatenation than supercoiling activity compared

    Synonyms: parD
  4. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263501] Unfortunately, complement C5 inhibition does not address C3-mediated extravascular hemolysis, which occurs earlier in the complement cascade within the alternative pathway. … [L50381] It was first approved in January 2024 in Japan for patients with PNH,[A263506,L50416] shortly after which the EMA adopted a positive opinion and recommended granting it marketing authorization

  5. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [L46287] It was fully approved by the EMA in May 2023.[L46596]

  6. Drug

    Liraglutide

    go.drugbank.com/drugs/DB06655
    ApprovedInvestigational

    Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine fo...

    Mixtures: XULTOPHY® SOLUCION PARA INYECCIÓN, XULTOPHY® SOLUCION PARA INYECCIÓN
  7. Drug

    Isavuconazole

    go.drugbank.com/drugs/DB11633
    ApprovedInvestigational

    It is proposed that the intravenous and oral dosing can be used interchangeably [L1482], without the need for a repeat loading dose when transitioning from an IV to an oral formulation [A32026]. … It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.

  8. Drug

    Sulpiride

    go.drugbank.com/drugs/DB00391
    ApprovedWithdrawn

    [A229683] Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.[L24679]

  9. Drug

    GSK-945237

    go.drugbank.com/drugs/DB15345
    Investigational

    GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose

  10. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.